This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Hang on a second…

This CME Activity has expired and is no longer available for credit.

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

New Pathways to Clearer Skin: Individualizing Treatment in Psoriasis

New Pathways to Clearer Skin: Individualizing Treatment in Psoriasis

Format

Interactive Monograph

Time to Complete

1.75 hours

Released

July 31, 2017

Expires

July 31, 2018
Add to Queue


Maximum Credits

1.75 / AMA PRA Category 1 CreditsTM

Accredited Provider

This activity is provided by the University of Cincinnati. Paradigm Medical Communications, LLC, is the educational partner.

Commercial Supporter

This activity is supported by educational grants from Janssen Biotech, Inc. and Novartis Pharmaceuticals Corporation.

Program Description

Psoriasis is the most prevalent and perhaps most distressing inflammatory disease in the United States. Aside from its cosmetic and emotional effects, the systemic inflammatory response associated with psoriasis increases the risk of cardiovascular disease, diabetes mellitus, hypertension, dyslipidemia, and other comorbidities. Newer biologic treatments that target pathways involved with the proinflammatory response offer patients new hope in combating psoriasis. Dermatologists and other clinicians who treat patients with psoriasis need education on the pathophysiologic targets of the newer agents and the guidelines that provide the framework for their use in order to identify patients who would benefit most from these treatments.

Agenda

  • Overview of Psoriasis
  • Signaling Pathways in Psoriatic Disease
  • New Therapies: Current and Ongoing Late-Phase Trial Data
  • Emerging agents and Their Targets
  • Treating the Psoriasis Patient: Case Studies and Patient Interaction

Intended Audience

This activity has been designed to address the educational needs of dermatologists. It may also be of benefit to primary care clinicians and other healthcare professionals who care for patients with psoriasis.

Educational Objectives

Upon proper completion of this activity, participants should be better able to:

  • Review the clinical guideline recommendations for earlier, aggressive treatment of moderate to severe plaque psoriasis as a systemic disease with systemic agents and/or biologic drugs
  • Explain newer pathways for the development of plaque psoriasis and their implications for determining treatment, based on current evidence
  • Summarize the most current evidence for newer therapies, which will guide patient selection, treatment goals, and response monitoring in patients with psoriasis

Conflict Of Interest Disclosure Policy

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Faculty

Jerry Bagel, MD
Director
Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ

Dr. Bagel discloses the following:
Grant/Research Support: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Novartis Pharmaceuticals Corporation
Retained Consultant: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals Inc.; Leo Pharma Inc.; Novartis Pharmaceuticals Corporation
Speakers Bureau: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Novartis Pharmaceuticals Corporation

Gary Goldenberg, MD
Assistant Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai Hospital
New York, NY

Dr. Goldenberg discloses the following:
Retained Consultant: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Valeant Pharmaceuticals International, Inc.
Speakers Bureau: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation
Honoraria: Valeant Pharmaceuticals International, Inc.

Accredited Provider Disclosure

Planning Committee Member
Barb Forney,
CME compliance - No Relevant Relationships

Rick Ricer, MD, Professor Emeritus, University of Cincinnati College of Medicine – No Relevant Relationships

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Credit

1.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The University of Cincinnati and Paradigm Medical Communications, LLC, are accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this enduring activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The University of Cincinnati designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please contact the University of Cincinnati at (513) 558-3197 or forneyba@uc.edu.

Disclosure of Unlabeled Use

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Disclaimer

The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, or Paradigm Medical Communications, LLC. The information is presented for the purpose of advancing the attendees’ professional development.

Signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, University of Cincinnati and Paradigm activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. In this activity, the trade names are used by the patient to describe his course of treatment. The use of trade names should not be viewed as an endorsement of specific products by University of Cincinnati, or Paradigm.

Instructions

To receive a CME certificate of participation, you should:

  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pretest.
  • View the online activity in its entirety.
  • Complete and submit the online post-test and evaluation. You must answer 70% of the post-test questions correctly to earn credit. You will have unlimited opportunities to successfully complete the post-test.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-test and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.

There is no fee required for participation in this activity.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

For information about the accreditation of this program, please contact the University of Cincinnati at (513) 558-3197 or forneyba@uc.edu.

Technical Support: If you have any technical problems or playback issues, please email Paradigm at contactus@paradigmmc.com.

Privacy Policy

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of University of Cincinnati, or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by University of Cincinnati, or Paradigm. The University of Cincinnati, and Paradigm accept no liability for the content referenced in this activity.

Privacy policy
The University of Cincinnati, and Paradigm are committed to protecting the privacy of those who participate in the activities (herein referred to as "website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by University of Cincinnati, and Paradigm to continuously improve the learning experience.

The University of Cincinnati, and Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. The University of Cincinnati, and Paradigm will not otherwise disclose personal information unless required to in a legal process. The University of Cincinnati, and Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.

Paradigm Medical Communications, LLC, privacy policy

myCME privacy policy

System Requirements

This certified CME activity is designed using HTML5 video and audio.

For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Copyright

© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Add to Queue